Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polvac Grass+Rye is an allergen extract suspension containing grass and rye pollen allergens adsorbed onto a microcrystalline tyrosine (MCT) adjuvant. Developed by the University of Zurich, it is designed for intralymphatic immunotherapy (ILIT) to treat allergic rhinitis and allergic asthma. The treatment protocol involves three ultrasound-guided injections into the inguinal lymph nodes over a 4-8 week period. This approach aims to induce immune tolerance more efficiently than traditional subcutaneous immunotherapy by delivering the allergens directly to the secondary lymphoid organs, potentially reducing the number of required doses and the overall duration of treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Polvac Grass+Rye.